Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;34(4):303-310.
doi: 10.1007/s40266-017-0446-x.

Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona

Laia Calvó-Perxas  1 , Oriol Turró-Garriga  1   2 , Joan Vilalta-Franch  1   2   3 , Manuela Lozano-Gallego  2 , Rosa de Eugenio  4 , Fabián Márquez  5 , Olga Carmona  6 , Jordi Gich  7 , Anna Manzano  8 , Marta Viñas  9 , Anna Mª Roig  10 , Josep Garre-Olmo  11   12   13 ; Registry of Dementias of Girona Study Group (ReDeGi Study Group)
Collaborators, Affiliations

Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona

Laia Calvó-Perxas et al. Drugs Aging. 2017 Apr.

Abstract

Background: Acetylcholinesterase inhibitors (AChEIs) and the N-methyl D-aspartate-antagonist memantine are indicated for the symptomatic treatment of Alzheimer's disease (AD).

Objectives: Our aims were to describe the baseline characteristics of patients with AD according to prescription of these treatments after the diagnostic work-up to describe long-term trends in the use of these medications and to identify baseline characteristics associated with the frequency of use of each treatment.

Methods: This was a cohort study with a sample of 2992 patients with AD recorded in the Registry of Dementias of Girona (ReDeGi) between 2007 and 2014. Consumption of AChEIs and memantine was assessed using the Pharmacy Unit database from the Public Catalan Healthcare Service. We used generalized estimating equation analyses to identify the baseline characteristics associated with the consumption of AChEIs and memantine over time.

Results: Most of the patients (70.4%; 95% confidence interval [CI] 68.7-72.0) were prescribed antidementia medication at the time of diagnosis. Of these, 75.0% (95% CI 73.1-76.8) were prescribed AChEIs, 14.7% (95% CI 13.2-16.3) were prescribed an AChEI plus memantine, and 10.3% (95% CI 9.0-11.6) were prescribed memantine. Advanced age reduced the likelihood of AChEI consumption. Mild dementia severity increased the use of AChEIs, and moderate-advanced dementia increased the likelihood of memantine consumption. After diagnosis, the likelihood of AChEI consumption decreased from the first year until the fifth, whereas the likelihood of memantine consumption, either alone or in combination with AChEIs, increased.

Conclusions: Antidementia drug use in this study showed the initial use of AChEIs alone with later use of AChEIs in combination with memantine and memantine alone in older patients with severe AD. Our findings are in agreement with current clinical practice guidelines for the pharmacological treatment of AD.

PubMed Disclaimer

References

    1. Int Psychogeriatr. 2015 Aug;27(8):1335-42 - PubMed
    1. Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):128-33 - PubMed
    1. BMC Neurol. 2009 Jan 28;9:5 - PubMed
    1. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154 - PubMed
    1. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593 - PubMed

LinkOut - more resources